Pyrazinamide resistance in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Abkhazia.

摘要

The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST) including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-amtnosalicylic acid, cycloserine) anti-TB drugs.